Durvalumab and tremelimumab before surgery for mesothelioma
Part of Cancer clinical trials.
This Phase 1/2 study tests the immune medicines durvalumab and tremelimumab, with or without chemotherapy, given before surgery for mesothelioma. It aims to shrink the tumor and improve safety and outcomes so more patients can have their cancer fully removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have mesothelioma that doctors think might be fully removed with surgery, based on CT/PET scans and a surgeon’s assessment
- Be able to have planned surgery after starting the study (either pleurectomy/decortication or extrapleural pneumonectomy)
- Be 18 or older, and well enough to participate (ECOG performance status 0–1)
- Have adequate blood counts and organ function (including kidney function and liver enzyme levels within limits)
- Have no prior treatment with PD-1 or PD-L1 medicines (including durvalumab) before starting this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy helps people with malignant mesothelioma live longer and feel better. It's for patients who can't have surgery or radiation, and it may be an option if you haven't had treatment before or have had limited prior treatment.
This trial tests a new combination of two immunotherapy drugs plus standard chemotherapy and a targeted therapy for people with advanced mesothelioma who have not had treatment before. The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests whether adding more chemotherapy directly into the belly after surgery can improve outcomes for people with a specific type of peritoneal mesothelioma. It may help reduce the chance of the cancer coming back.
This early-phase study tests a treatment that uses a patient’s immune cells (dendritic cell therapy) combined with surgery for epithelioid mesothelioma. It aims to help the immune system better recognize and attack the cancer after chemotherapy and before/around surgery.
This trial tests whether giving chemotherapy and immunotherapy before planned surgery can make inoperable pleural mesothelioma operable. It is for people with a specific type of mesothelioma (epithelioid) that cannot be removed right away, to see if the treatment shrinks the tumor enough for surgery later.
This trial studies how well pembrolizumab (an immune therapy) works when added to chemotherapy before image-guided surgery for malignant pleural mesothelioma. It aims to shrink or control the cancer and improve surgical results by combining treatments.
Hear when a new Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.